These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 24481312)

  • 1. PI3K and cancer: lessons, challenges and opportunities.
    Fruman DA; Rommel C
    Nat Rev Drug Discov; 2014 Feb; 13(2):140-56. PubMed ID: 24481312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the phosphoinositide 3-kinase pathway in cancer.
    Liu P; Cheng H; Roberts TM; Zhao JJ
    Nat Rev Drug Discov; 2009 Aug; 8(8):627-44. PubMed ID: 19644473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
    Cho DC
    BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of PI3K inhibitors: lessons learned from early clinical trials.
    Rodon J; Dienstmann R; Serra V; Tabernero J
    Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
    Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
    Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
    Manfredi GI; Dicitore A; Gaudenzi G; Caraglia M; Persani L; Vitale G
    Endocrine; 2015 Mar; 48(2):363-70. PubMed ID: 25115638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors.
    Zhang Y; Yan H; Xu Z; Yang B; Luo P; He Q
    Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):767-774. PubMed ID: 31478386
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
    LoPiccolo J; Blumenthal GM; Bernstein WB; Dennis PA
    Drug Resist Updat; 2008; 11(1-2):32-50. PubMed ID: 18166498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
    Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
    Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
    Owonikoko TK; Khuri FR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.